NASDAQ · ALGN
Healthcare · Medical - Devices
$154.96
Down-$4.83 (-3.02%)
Updated Sep 2, 2026, 1:06 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ALGN closed at $154.96 after 21 trading sessions, down 10.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $158.21 | $159.33 | $153.98 | $154.96 | 576.46K |
| Aug 31, 2026 | $155.36 | $160.48 | $154.50 | $159.79 | 1.29M |
| Aug 28, 2026 | $158.51 | $159.965 | $157.21 | $157.58 | 954.65K |
| Aug 27, 2026 | $157.80 | $162.09 | $157.77 | $158.84 | 801.29K |
| Aug 26, 2026 | $158.85 | $161.66 | $158.53 | $159.14 | 653.66K |
| Aug 25, 2026 | $158.85 | $160.69 | $157.27 | $159.61 | 811.64K |
| Aug 24, 2026 | $162.25 | $162.80 | $159.07 | $159.64 | 762.05K |
| Aug 21, 2026 | $159.74 | $162.77 | $157.385 | $162.55 | 1.08M |
| Aug 20, 2026 | $162.52 | $164.6396 | $157.34 | $158.94 | 836.76K |
| Aug 19, 2026 | $170.02 | $173.665 | $162.615 | $163.04 | 928.99K |
| Aug 18, 2026 | $171.57 | $172.365 | $167.78 | $167.91 | 744.75K |
| Aug 17, 2026 | $179.05 | $181.33 | $170.16 | $171.16 | 916.81K |
| Aug 14, 2026 | $176.73 | $182.20 | $176.72 | $181.31 | 959.98K |
| Aug 13, 2026 | $175.61 | $176.49 | $172.85 | $176.20 | 541.59K |
| Aug 12, 2026 | $172.96 | $174.74 | $169.46 | $174.015 | 658.42K |
| Aug 11, 2026 | $174.67 | $178.4623 | $172.80 | $172.955 | 550.3K |
| Aug 10, 2026 | $173.02 | $176.485 | $172.70 | $176.04 | 643.61K |
| Aug 7, 2026 | $169.15 | $173.84 | $165.00 | $173.66 | 870.1K |
| Aug 6, 2026 | $173.43 | $174.09 | $168.67 | $169.08 | 655.76K |
| Aug 5, 2026 | $170.89 | $175.54 | $170.885 | $174.83 | 1.02M |
| Aug 4, 2026 | $172.10 | $174.33 | $170.50 | $173.27 | 1.12M |
The latest Smart Investors Daily articles mentioning ALGN.
ALGN research
Company profile and research snapshot.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | BMO Capital | Outperform | — |
| Apr 30, 2026 | Evercore ISI Group | Outperform | — |
| Apr 24, 2026 | Morgan Stanley | Equal-Weight | — |
| Apr 21, 2026 | Piper Sandler | Overweight | — |
| Apr 15, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 21, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
SeekingAlpha · Aug 17, 2026
ChartMill · Aug 13, 2026
Align Technology (ALGN) appears undervalued with strong profitability, no debt, and decent growth, fitting the Decent Value screen.
Yahoo · Aug 12, 2026
Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China i
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALGN.
